Galectin Therapeutics (GALT) Profit After Tax (2010 - 2026)
Galectin Therapeutics' (GALT) quarterly Profit After Tax came in at -$5.0 million in Q1 2026, up 47.61% year-on-year from -$3.4 million in Q1 2025, and up 8.25% quarter-over-quarter from -$5.5 million in Q4 2025.
Galectin Therapeutics (GALT) Profit After Tax (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$5.0 million for Q1 2026.
- On a quarterly basis, Profit After Tax rose 47.61% year-over-year to -$5.0 million in Q1 2026; TTM through Mar 2026 was -$26.3 million, a 41.91% increase from a year earlier, with the FY2025 full-year figure at -$30.8 million, up 34.46% from the prior year.
- Profit After Tax rose to -$5.0 million in Q1 2026 per GALT's latest filing, from -$5.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$5.0 million in Q1 2026 and bottomed at -$12.4 million in Q2 2024.
- The 5-year median for Profit After Tax is -$9.9 million (2022), against an average of -$9.6 million.
- Across the five-year window, Profit After Tax slumped 56.71% in 2022 and jumped 54.04% in 2025, its largest moves.
- Year by year, Profit After Tax stood at -$10.6 million in 2022, then climbed by 5.99% to -$10.0 million in 2023, then fell by 19.71% to -$12.0 million in 2024, then soared by 54.04% to -$5.5 million in 2025, then grew by 8.25% to -$5.0 million in 2026.
- Per Business Quant, the three latest GALT Profit After Tax figures stand at -$5.0 million (Q1 2026), -$5.5 million (Q4 2025), and -$8.2 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - | -5.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.05 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | -8.18 Mn |
| Jun 30, 2025 | -7.52 Mn |
| Mar 31, 2025 | -9.63 Mn |
| Dec 31, 2024 | -11.97 Mn |
| Sep 30, 2024 | -11.22 Mn |
| Jun 30, 2024 | -12.37 Mn |
| Mar 31, 2024 | -11.49 Mn |
| Dec 31, 2023 | -10.00 Mn |
| Sep 30, 2023 | -10.43 Mn |
| Jun 30, 2023 | -9.11 Mn |
| Mar 31, 2023 | -11.53 Mn |
| Dec 31, 2022 | -10.63 Mn |
| Sep 30, 2022 | -8.60 Mn |
| Jun 30, 2022 | -9.61 Mn |
| Mar 31, 2022 | -9.93 Mn |
| Dec 31, 2021 | -7.22 Mn |
| Sep 30, 2021 | -8.52 Mn |
| Jun 30, 2021 | -8.45 Mn |